(A61K31/495)

Semi-synthetic derivatives of heliomycin inhibiting tumor growth // 2644780
FIELD: pharmaceutics.SUBSTANCE: invention relates to 4-aminomethyl heliomycin derivatives corresponding to the formula: as well as to pharmaceutical compositions based on them.EFFECT: technical result: new compounds are obtained with the ability to inhibit the division of tumor cells.6 cl, 18 ex, 1 tbl
2-(4-bromophenylamino)-1-(piperazin-1-yl)-4-phenylbut-2-en-1,4-dione hydrochloride having insecticidal effect // 2644162
FIELD: chemistry.SUBSTANCE: invention relates to 2-(4-bromophenylamino)-1-(piperazin-1-yl)-4-phenylbut-2-en-1,4-dione hydrochloride of the formula: .EFFECT: compound with a high insecticidal effect and low toxicity is produced.1 tbl, 1 ex

Pharmaceutical combined drug // 2639818
FIELD: pharmacology.SUBSTANCE: invention relates to a drug for prevention or treatment of cardiovascular diseases comprising a granulated portion of fimsartan and a mixed portion of rosuvastatin, as well as meglumine.EFFECT: excellent effect in treatment of cardiovascular disease due to improved dissolution and dilution of the active substances, which provides better bioavailability and safety of the drug.19 cl, 5 ex, 3 tbl, 1 dwg
ethod for correction of psychosomatic diseases in patients with irritated bowel syndrome // 2637628
FIELD: medicine.SUBSTANCE: for correction of anxiety and depression in patients with irritable bowel syndrome 10 mg of "Cipralex" 1 time per day for three months, or 25 mg of "Atarax" 1 pill 2 times a day for two months and "Enterosan" 1 capsule 3 times a day 15-20 minutes before meals are prescribed for two months alongside with a diet.EFFECT: method allows to reduce regression times of pain and dyspeptic syndromes.2 ex
Procaspase combined therapy with glyblastoma // 2636234
FIELD: biotechnology.SUBSTANCE: group of inventions refers to a composition for combined procaspase therapy containing a compound of formula and a PAC-1: compound, as well as a method for suppressing the growth and/or proliferation of glioblastoma cells, oligodendrogliomas or osteosarcomas; to the method for inducing apoptosis of brain cancer cells or bone cancer cells; to the method for treating brain cancer or bone cancer; and to the use of a composition for preparing a medicament for the treatment of brain cancer or bone cancer.EFFECT: synergistic action of the composition components.22 cl, 4 dwg, 2 ex
Compositions containing vortioxetine and donepezil // 2635528
FIELD: pharmacology.SUBSTANCE: invention is a pharmaceutical composition comprising vortioxetine and donepezil together with a pharmaceutically acceptable excipient, the composition is for treatment of a disease selected from cognitive dysfunction, dementia in Alzheimer's disease, dementia of vascular genesis, dementia in Pick's disease, dementia in Creutzfeldt-Jakob disease, dementia in Huntington's disease, dementia in Parkinson's disease, dementia in the human immunodeficiency virus, dementia in persons abusing alcohol or medication, moderate cognitive impairment, cognitive dysfunction associated with depression, and cognitive dysfunction associated with schizophrenia.EFFECT: invention provides a synergistic increase in the extracellular level of acetylcholine in the brain.12 cl, 5 ex, 1 tbl, 6 dwg
ethod of medically induced support of patients during implementation of osteoplastic operations // 2631416
FIELD: medicine.SUBSTANCE: seven days prior to the operation and within three weeks after the operation, the patient is administered the drug Trental in tablets at a dose of 100 to 400 mg and the drug Actovegin by 1 pill up to three times a day. As an antibacterial agent on the day of the operation and within six days after it, Klacid SR is administered at a dose of 500 mg by 1 tablet 2 times a day. From the first day after the operation until the removal of the sutures, Zyrtec is administered at a dose of 10 mg by 1 tablet per day. For anesthesia, the patient is administered a selective COX-2 inhibitor by 1 tablet after a meal. From the first day after the operation until the removal of the sutures, PerioKin gel is topically applied to the patient's surgery area 2-3 times a day. Within three weeks after the operation, ultraviolet gum irradiation and local laser therapy are performed, alternating these physiotherapeutic procedures daily. From the third day after the operation, paste and rinse after toothbrushing KIN® GINGIVAL ALPHANTA are used 2-3 times a day after a meal. 3 weeks after the operation Osteogenon drug is administered by 1 tablet twice a day and Chlorophyll Forte GP drug is administered by 1 capsule 1 time per day.EFFECT: improvement of microcirculation and trophism of tissues in the operated zone, creation of optimal conditions for reparative osteogenesis in the field of plastic and wound healing, prevention of postoperative complications concerning soft tissues.1 ex

Pharmaceutical compositions containing carbamoyloxyarylalcanoylarylpiperazine compound // 2630619
FIELD: pharmacology.SUBSTANCE: pharmaceutical composition for prevention or treatment of a disease associated with 15-lipoxygenase, comprising a therapeutically effective amount of a compound of 3-[4-(3,4-dimethoxyphenyl)-piperazine-1-yl]-3-oxo-1-phenylpropyl ester of (R) carbamic acid. The invention also relates to a method for treatment of a disease associated with 15-lipoxygenase, as well as a pharmaceutical composition with inhibitory activity.EFFECT: implementation of the invention allows to increase the effectiveness of prevention or treatment of diseases associated with 15-lipoxygenase, such as diabetic nephropathy, diabetic neuropathy, vascular complications of diabetes, hyperlipidemia and inflammatory reactions induced by diabetes.3 cl, 15 ex, 2 tbl, 6 dwg

Pyperazinyl derivatives for cancer treatment // 2629115
FIELD: pharmacology.SUBSTANCE: invention relates to a compound of the general formula (I), where X represents a (C1-C6)alkyl, phenyl, benzyl, C(O)OR5 or C(O)NHR5 group; R1 represents a hydrogen atom or a C(O)R6 or C(O)OR6 group; R2 represents a hydrogen atom or a (C1-C6)alkyl group; or R2 together with R1 or X form a saturated hydrocarbon chain that forms a 5- or 6-member ring; R3 represents a hydrogen atom or a (C1-C6)alkyl group; R4 represents a halogen atom or a (C1-C6)alkyl, (C1-C6)alkoxy or phenyloxy group, the said group being optionally substituted by one or more halogen atoms; Ar represents a thiophenyl or phenyl group optionally substituted by one halogen atom; and R5 and R6 independently of each other represent a (C1-C6)alkyl, phenyl-(C1-C6)alkyl group or phenyl optionally substituted by one halogen atom. The invention also relates to a pharmaceutical composition and to a process for preparation of general formula (I) compounds.EFFECT: new piperazinyl compounds of the general formula are obtained that can be used for breast cancer, leukemia, colon cancer, pancreatic cancer and ovarian cancer treatment or prevention.12 cl, 1 dwg, 6 tbl, 8 ex

Amide compounds, methods for production, application as means for treatment and prevention of diseases caused by rna-containing viruses // 2628800
FIELD: pharmacology.SUBSTANCE: compounds of the invention are intended for manufacture of a pharmaceutical composition, kit or drug. The invention also relates to a process for preparation of compounds of the invention (versions). Compounds of the invention are intended for use in the prevention or treatment of diseases caused by RNA-containing viruses belonging to enteroviruses, metapneumoviruses or pneumoviruses.EFFECT: amide compounds for treatment or prevention of diseases caused by RNA-containing viruses.26 cl, 8 tbl, 5 ex

ethod of production of a combined antihelmint tablet with a symbiotic treatment for treatment of a small cattle // 2627893
FIELD: veterinary medicine.SUBSTANCE: invention is a method for producing a combined anthelmintic tablet with a symbiotic for treating small cattle containing a first and second layer comprising the steps of: adding a first powder mixture to a mould plate. Mentioned first powder mixture contains a pharmaceutically active substance and a binder, a second powder mixture is added to said mould plate. Mentioned second powder blend comprises a binder and the composition of mentioned second powder blend is different from the composition of mentioned first powder mixture, the first powder mixture and the second powder blend are pressed on said plate of the mould to form a tablet form and subjected to said tableted form with radio frequency emission for a period of Time sufficient to activate said binder within said tablet mould to fuse mentioned tableted Th form into said tablet, such that the density of mentioned tablet is less than about 0.8 g/cm3, characterized in that a bacterial concentrate is prepared for the preparation of the first powder mixture comprising a bifidobacterium adolescentis B-1 and Lactobacillus acidophilus LH-1 consortium with a titre of 108-1010 CFU/g sorbed on a carrier in a ratio of 1:1:12, which Is concentrated by filtration or centrifugation to a suspension containing 5 billion bacteria per ml, followed by mixing them in equal volumes. As the carrier, flour or bran is used at the rate of 12 parts of the support per part of a mixture of concentrated cultures, and then the obtained dry powder mass is mixed with lactulose, and to obtain the second powder mixture, ivermectin, praziquantel and at least one pharmaceutically acceptable excipient microcrystalline cellulose MCC is used, then the substances ivermectin, praziquantel and excipient are mixed in dry kind. The components in the tablet are in a certain ratio in wt %.EFFECT: invention provides high anthelmintic activity, intensification of treatment and prevention of a number of helminthic invasions, nonspecific correction of the immune response of the animal organism, normalization of hepatoprotective and reparative liver functions.6 ex, 1 tbl, 1 dwg
Piperazine derivatives, their preparation and application for insulin resistance treatment // 2626965
FIELD: pharmacology.SUBSTANCE: invention relates to a compound of formula (1), as well as to methods for its preparation, and pharmaceutical compositions based thereon.EFFECT: new compounds have been obtained that can be used for treatment of pathologies associated with insulin resistance syndrome, for example, type 2 diabetes.8 cl, 1 tbl, 2 ex

Pharmaceutical composition for extended trimetazidine release // 2621128
FIELD: medicine, pharmacy.SUBSTANCE: invention relates to pharmacy. The composition comprises an inner phase and an outer layer. The inner layer is composed of coated trimetazidine dihydrochloride in a neutral nucleus and hydroxypropylmethylcellulose. The outer layer comprises ethyl cellulose, acetyl tributyl citrate, and talc. These components are contained in the following amounts: trimetazidine dihydrochloride - 80 mg, neutral core - 36.677 mg hydroxypropyl methylcellulose - 6.40 mg, acetyl tributyl citrate - 1.2 mg ethylcellulose - 8 mg, talc - 12 mg. The invention provides a composition with prolonged trimetazidine release for over 24 hours with therapeutic concentration levels in blood maintained for 24 hours.EFFECT: pharmaceutical composition is used for prolonged trimetazidine release.3 cl, 5 dwg, 3 tbl, 3 ex
Piperazine derivatives, their preparation and their use in treatment of insulin resistance // 2619110
FIELD: chemistry.SUBSTANCE: invention relates to the heterocyclic compound of the formula and its enantiomer, diastereoisomer and addition salts of the pharmaceutically acceptable bases or acids, where R1 refers to the group of -C(O)CR3R4CR5R6C(O)OH or the group of ; n and m refer to 0 or 1; L1 - group C (O) -; -C (O) O- or -S (O)2-; R2 refers to the carbocyclic aromatic group having 6 members, unsubstituted or substituted with one or more substituents, identical or different, selected from the alkoxy group having 1-6 carbon atoms, linear or branched, of halogen, CF3, the cyano-group (-CN), the sulfonylmethyl group (-S (O)2-methyl); the heterocyclic aromatic group with 5 or 6 members containing 1 or 2 heteroatoms, identical or different, selected from nitrogen and sulfur; the polyheterocyclic aromatic group with 9 members, with 3 heteroatoms, identical or different, selected from nitrogen and sulfur; the L2 is - carbocyclic group, wherein the carbocycle refers to the aromatic cycle with 6 members ; or the hydrocarbon group, linear or branched, with 1 to 5 carbon atoms; L2 refers to alkyl, linear or branched, with 1 to 5 carbon atoms; R3, R4, R5 and R6 refer to hydrogen atom; R7, identical or different, refers to alkyl, linear or branched, with 1 to 5 carbon atoms. The invention also relates to the process for preparing a compound of the formula (1) and the pharmaceutical composition based on the compounds of the formula (1).EFFECT: new heterocyclic compounds are obtained, useful in the treatment of pathologies associated with insulin resistance syndrome.11 cl, 1 tbl 5 ex
ethod for skeletal muscle experimental ischemia pharmacological correction using vardenafil and pentoxifylline in combined therapy // 2618622
FIELD: medicine.SUBSTANCE: for skeletal muscle ischemia correction on the background of skeletal muscle ischemia simulation, its correction is performed by daily intragastric administration of a combination of vardenafil at a dose of 0.09 mg kg and pentoxifylline at a dose of 30 mg/kg 1 time a day, for 7 days.EFFECT: method provides good rheological effect in the ischemia hearth at lower drugs doses and safety of their use in terms of side effects of treatment.1 tbl, 1 ex
ethod for skeletal muscle experimental ischemia pharmacological correction using sildenafil and pentoxifylline in combined therapy // 2618621
FIELD: medicine.SUBSTANCE: for skeletal muscle ischemia correction on the background of skeletal muscle ischemia simulation, its correction is performed by daily intragastric administration of a combination of sildenafil at a dose of 0.22 mg kg and pentoxifylline at a dose of 30 mg/kg 1 time a day, for 7 days.EFFECT: method provides good rheological effect in the ischemia area at lower drugs doses and safety of their use.1 ex, 1 tbl
ethod for skeletal muscle experimental ischemia pharmacological correction using tadalafil and pentoxifylline in combined therapy // 2618620
FIELD: medicine.SUBSTANCE: for skeletal muscle ischemia correction on the background of skeletal muscle ischemia simulation, its correction is performed by daily intragastric administration of a combination of tadalafil at a dose of 0.09 mg kg and pentoxifylline at a dose of 30 mg/kg 1 time a day, for 7 days.EFFECT: method provides good rheological effect in the ischemia hearth at lower drugs doses and safety of their use in terms of side effects.1 tbl

Sustained release pill, containing levodropropizine, and manufacturing method thereof // 2616263
FIELD: medicine, pharmacy.SUBSTANCE: this invention refers to a sustained-release pill containing levodropropizine with antitussive and expectorant effect. The presented levodropropizine sustained-release pill consists of: an immediate release layer comprising levodropropizine and a sustained release layer comprising levodropropizine and a release controlling polymer.EFFECT: invention extends the product range of pharmaceuticals with delayed release.3 cl, 4 tbl, 2 ex, 6 dwg

Heterocyclic compounds useful as pdk1 inhibitors // 2615130
FIELD: chemistry.SUBSTANCE: present invention relates to novel compounds of general formulae II, III, IV and V, where values of radicals are given in description, or pharmaceutically acceptable salts thereof, which can be used as PDK1 inhibitors.EFFECT: present invention also relates to pharmaceutical compositions based thereon and to methods of treating cancer, mediated by protein kinase PDK1.32 cl, 2 tbl, 445 ex

Stable pharmaceutical composition for oral administration comprising levocetirizine, or pharmaceutically acceptable salt thereof and montelukast or pharmaceutically acceptable salt thereof // 2614382
FIELD: medicine, pharmacy.SUBSTANCE: this present invention relfers to a pharmaceutical composition in the form of a capsule for oral administration for asthma or allergic rhinitis prevention or treatment. The composition comprises: (a) the first fraction of particles in the form of mini-pill comprising levocetirizine, or pharmaceutically acceptable salt thereof and organic acid; and (b) the second fraction of particles in the form of mini-pill comprising montelukast or pharmaceutically acceptable salt thereof. The organic acid is citric acid, tartaric acid, succinic acid or ascorbic acid. The organic acid is present in the amount of 100 parts by weight per 100 parts of levocetirizine. The said first and second particle fractions are physically separated and filled into the capsule. A method for pharmaceutical capsule composition production is also described. The pharmaceutical composition of this invention inhibits the production of related contaminants of levocetirizine and montelukast and provides good stability.EFFECT: invention expands the product range of drugs for allergic rhinitis or asthma prevention or treatment.9 cl, 3 dwg, 4 tbl, 6 ex
Composition based on r(-)-praziquantel for treating and preventing helminthiasis in warm-blooded animals // 2613490
FIELD: pharmaceutics.SUBSTANCE: invention refers to pharmaceutics and can be used for treating and preventing helminthiasis in warm-blooded animals, including agricultural and domestic animals, in particular cats and dogs. For this anthelminthic composition is proposed containing as an active agent combination of praziquantel enantiomer (R-praziquantel, R-PZQ), presented in the form of complex with beta-cyclodextrin, and pyrantel pamoat, as well as water and vegetable oil, neutral filler and auxiliary additives, particularly additive with hepatoprotective and GIT microflora recovering action in following proportions (wt%): R-praziquantel 0.1–0.5, pyrantel pamoat 1.0–3.0, beta-cyclodextrin 1.5–5.0, fillers and auxiliary additives 1.2–5.3, vegetable oil 4.0–22.0, water – rest. Proposed water-oil suspension is characterized by wide spectrum of action, storage stability, ease of use, texture and taste, acceptable for animals, and differs from known analogues in higher efficacy of cystocidal action, achieved due to possibility of 2-5-fold reduction of effective dose of R(-)-praziquantel in comparison with conventionally used racemic mixture.EFFECT: invention provides improved consumption by animals, including any kinds of dogs, kittens and puppies, as well as aged and/or debilitated animals.6 cl, 9 tbl, 5 ex
ethod for production of antiparasitic long acting preparation for animals // 2611387
FIELD: veterinary medicine.SUBSTANCE: praziquantel, ivermectin, copolymer of lactic and glycolic acids are mixed with a solvent with the following ingredient ratio (in wt %): praziquantel - 1.0-15.0, ivermectin - 0.5-8.0, copolymer of lactic and glycolic acids - 6.0-16.5, solvent - the rest. At that,praziquantel and ivermectin are the first to be dissolved in the solvent. The solution is then purged with argon or nitrogen and placed in an ultrasonic bath. The mixture is kept in the ultrasonic bath for 50-60 minutes till complete dissolution of the components. Then the copolymer of lactic and glycolic acids is added. For complete copolymer dilution, the obtained mixture is kept for 4-5 hours with occasional stirring at the rotation speed of 1600-2000 rpm. Then, the resulting solution is subjected to sterile filtration, dispensed into vials and sealed.EFFECT: method can reduce loss of active ingredients during manufacture and provide a harmless, non-toxic, sterile and effective long-acting drug for treating animals against a wide range of parasitic infections.5 cl, 8 ex

Lysin-specific demethylase-1 inhibitors and use thereof // 2602814
FIELD: chemistry.SUBSTANCE: invention relates to organic chemistry, specifically to a heterocyclic compound of general formula (I), where (A) denotes phenyl or pyridyl; each (A′), if present, is independently selected from a group consisting of phenyl, phenylC1-C10alkoxy group, phenylC1-C-10alkyl, phenyloxy group and halogen, where each (A′) contains 0, 1, 2 or 3 substitutes independently selected from a group, including halogen, halogenC1-C-10alkyl, phenyl, C1-C10alkyl and C1-C10alkoxy group; X equals 0, 1 or 2; (B) denotes cyclopropyl ring, where (A) and (Z) are covalently bonded to different carbon atoms in (B); (Z) denotes -NH-; (L) is selected from -CH2CH2-, -CH2CH2CH2- and -CH2CH2CH2CH2-; and (D) is selected from -N(-R1)-R2, -O-R3 and -S-R3, where R1 and R2 are bonded to each other, and together with a nitrogen atom to which R1 and R2 are bonded, form a 5- or 6-member heterocyclic ring, where said heterocyclic ring contains 0, 1 or 2 substitutes, independently selected from a group comprising -NH2, -NH(C1-C6-alkyl), -N(C1-C6-alkyl)(C1-C6-alkyl) and C1-C10alkyl, or R1 and R2 are independently selected from a group including -H, C1-C-10alkyl and C3-C7-cycloalkyl, where total number of substitutes in R1 and R2 is equal to 0, 1 or 2 and substitutes are independently selected from -NH2, -NH(C1-C6-alkyl) and -N(C1-C6-alkyl) (C1-C6-alkyl); and R3 denotes C1-C10alkyl; or its enantiomer, diastereomer or mixture thereof, or its pharmaceutically acceptable salt or solvate; provided that following compounds are excluded: N1,N1-dimethyl-N2-(2-phenylcyclopropyl)-1,3-propandiamine and N1,N1-dimethyl-N2-(2-phenylcyclopropyl)-1,2-ethanediamine. Invention also relates to a heterocyclic compound of formula (I'), a pharmaceutical composition based on compound of formula (I) and use of compound of formula (I).EFFECT: technical result is obtaining novel heterocyclic compounds having activity as a LSD1 inhibitor.29 cl, 7 dwg, 1 tbl, 40 ex (I) (I')

Trans-2-decenoic acid derivative and medicinal agent containing same // 2602810
FIELD: chemistry.SUBSTANCE: present invention relates to a novel trans-2-decenoic acid derivative of formula (I') or a pharmaceutically acceptable salt thereof , possessing preventive or therapeutic effect for peripheral nervous system disorders, caused by anti-cancer agents, and/or neurotrophic factor-like activity and/or analgesic action, as well as to a pharmaceutical agent based thereon.EFFECT: prevention and treatment of nervous system disorders.14 cl, 11 tbl, 56 ex

Anti-inflammatory and/or antinociceptive (z)-3-(2-oxo-2-(4-tolyl) ethylidene)piperazine-2-on, method for production thereof, pharmaceutical compositions // 2602500
FIELD: pharmaceutics.SUBSTANCE: invention relates to a drug for treating inflammatory diseases of a locomotor system, accompanied by a pain syndrome, (Z)-3-(2-oxo-2-(4-tolyl)ethylidene)piperazine-2-on of formula (I), and method for production thereof.EFFECT: treating inflammatory diseases of a locomotor system.3 cl, 2 tbl, 5 ex

ethod of detecting anticonvulsant action of sodium citicoline and valproate when applying them together on model of acute generalized convulsions caused by pentylenetetrazole in wistar male rats // 2600477
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to neurochemistry, pathophysiology, neurology and psychiatry. On the model of acute generalized convulsions, caused by pentylenetetrazole in Wistar male rats, the method of anticonvulsant action when applying sodium citicoline and sodium valproate is disclosed. Preparations are being intraperitoneally administered, at that, citicoline is being administered in a dose of 300 mg/kg one hour before the administration of pentylenetetrazole, sodium valproate is being administered in a dose of 70 mg/kg 10 minutes before the administration of pentylenetetrazole.EFFECT: selected dose schedule of the preparations provides higher anticonvulsant action also related to the neuroprotective action of preparations, which reduces the neurodegeneration in the rat brain under conditions of acute generalized convulsions caused by pentylenetetrazole.1 cl, 3 tbl

Substituted benzamide derivatives // 2595902
FIELD: chemistry.SUBSTANCE: invention relates to compound of formula (I), where R is hydrogen or C1-7alkyl; R1 represents -(CH2)n-(O)o-5-7-member heterocycloalkyl, containing 1-2 heteroatoms selected from N and O, except for piperazine, where said heterocycloalkyl group optionally substituted with C1-7alkyl, hydroxy or halogen; n equals to 0, 1 or 2; o equals to 0 or 1; R2 represents CF3, C3-6-cycloalkyl, possibly substituted C1-7alkoxy or halogen, or represents indane-2-yl, or is 6-member heterocycloalkyl, containing 1-2 heteroatoms selected from N and O, optionally substituted with pyrimidinyl, or is 5-6 mono- or 9-10-member bicyclic heteroaryl containing 1-2 heteroatoms selected from N, O and S, where the heteroaryl is not thiazol and where said aromatic ring, is possibly substituted with one or two substitutes selected from C1-7alkyl, halogen, 5-6-member heteroaryl containing 1-2 heteroatoms selected from N and O, hydroxy, CF3, OCF3, OCH2CF3, OCH2-cycloalkyl, OCH2C(CH2OH)(CH2Cl)(CH3), S-C-1-7alkyl, C1-7alkoxy, CH2-C-1-7alkoxy, C2-7alkynyl or cyano, or substituted with -C(O)-phenyl, -O-phenyl, -O-CH2-phenyl, phenyl, and where said phenyl ring may be substituted with halogen, -C(O)OH or -C(O)O-C-1-7alkyl, or said aromatic ring, is possibly substituted with 5-6-member heterocycloalkyl, containing 1-2 heteroatoms selected from N and O, OCH2-oxetane-3-yl or O-tetrahydropyran-4-yl, possibly substituted C1-7alkyl; X is bond, -CH2NH-, -CHR″-, -(CHR″)q-O-, -O-(CHR″)q- or -(CH2)2-; Y is bond; R″ is hydrogen, C1-7alkyl, CF3, C1-7alkoxy; q is equal to 0, 1, 2 or 3; or pharmaceutically acceptable acid addition salt thereof, except for compounds specified in patent claim. Invention also relates to specific compounds specified in patent claim. Compounds are intended for producing medicinal agents, showing affinity to TAAR1.EFFECT: technical result: benzamide derivatives having high affinity to receptors associated with TAAR1 trace amines.9 cl, 1 tbl, 323 ex

Solid dosage form of preparation of sedative and hypnotic effect // 2589833
FIELD: medicine.SUBSTANCE: invention relates to a solid dosage form of sedative and hypnotic effect. Said dosage form is a tablet or capsule, which contains hydroxyzine in amount of 3.33 to 4.5 wt%, ethyl ether of α-bromo-isovaleric acid in amount of 5.47 to 7 wt%, peppermint oil or mixture thereof with hop oil in amount from 0.39 to 0.48 wt%, β-cyclodextrin in amount of 37-50 wt% and additives, including combined water.EFFECT: invention is characterised by high sedative properties and hypnotic efficiency compared to existing analogues, which provides long sleep duration and faster onset thereof.3 cl, 3 tbl, 3 ex

Fatty acid fumarate derivatives and uses thereof // 2588256
FIELD: chemistry.SUBSTANCE: invention relates to novel compounds of formula I or pharmaceutically acceptable salts thereof, enantiomers or stereoisomers; in which values for groups W1, W2, R3, L, Z, a, b, m, c, d, etc. are defined in patent claim.EFFECT: invention also refers to pharmaceutical compositions based on said compounds possessing inhibitory activity on NF-kB, for treating inflammation or inflammatory disease, type II diabetes, insulin-resistant cardiovascular disease, arrhythmia, atherosclerosis, coronary artery disease, hypertriglyceridemia, dislipidemia, retinopathy, neuropathy, macular edema, diabetic nephropathy, IgA nephropathy, CLD, inflammatory diseases of kidneys.25 cl, 4 dwg, 25 ex, 1 tbl
ethod for integrated treatment of postpartum endometritis in suture inconsistency on uterus after caesarean section by controlled negative pressure // 2587034
FIELD: medicine.SUBSTANCE: therapeutic-diagnostic laparoscopy is performed, during which sanation of small pelvis with 0.5 % chlorhexidine solution is carried out. Removing collected effusion, in front of and behind uterine space draining with silicone tubes with diameter of 8-9 mm. Under laparoscopic control hysteroscopy is carried out with washing of uterine cavity with 0.5 % chlorhexidine solution. Double-barreled silicone tube with diameter of 6 mm is passed through uterine cavity, its intrauterine part is wrapped with foam sponge, impregnated with activated carbon, tube is anchored to cervix by separate vicryl suture. Tight cap is worn on neck of uterus, 400 ml of 0.5 % solution of dioxydine at temperature +2…+4 °C is fed through tube into uterine cavity fractionally every 8 hours. Sprinkling with 400 ml of ozonised 0.9 % saline solution with simultaneous aspiration of content of cavity and continuously maintaining negative pressure in uterine cavity within range of 50-70 mm Hg using a RENASYS GO device and simultaneously through silicone tubes located in front of and behind uterine spaces, into abdominal cavity is fed ozonised saline solution in amount 400 ml twice a day with exposure of 30 minutes. Treatment is performed with underlying uterotonic, antibacterial therapy.EFFECT: method enables to localise process within lesser pelvis, creates conditions for distinction of process, keeps moist environment, stimulating angiogenesis, reinforcing fibrinolysis, promotes functioning growth factors, thereby improving blood circulation in wall of uterine cavity, considerably reduces possibility of contamination of pathological microflora in uterine wall thickness, thus reduces inflamed tissue oedema, improves contractile function of uterus, cleansing and regression of inflammatory process in endometrium and myometrium.1 cl, 1 ex

Composition of agents for detecting epithelial tumour cells and preparation method thereof // 2585114
FIELD: chemistry.SUBSTANCE: invention relates to a composition of agents for detecting living cells, in particular for epithelial tumour cells; composition contains 0-5 % folic acid, 0-10 % folic acid composite, 0.01 - 5% methylene blue, 0.1-10 % carbohydrate reducing agent, 2-6 % acetic acid and 3-95 % water.EFFECT: present invention also relates to a method of preparing a composition for detecting agents and kits containing composition of detection agents.21 cl, 1 tbl, 6 ex
ethod of treating chronic diseases based on modulation of antiviral immunity // 2582295
FIELD: medicine.SUBSTANCE: invention relates to medicine, specifically to therapy, and can be used for treatment of chronic diseases, burdened herpes virus latent infection. Method involves introduction of chemopreparations and preparations of medicinal plants and physiotherapeutic exposure stimulating interstitial humoral transport and lymphatic system function. Introduction of preparations and physiotherapeutic exposure is combined with hepatotrophic agents, normalising gastric and intestinal intake of intestinal chelators, vitamins and trace elements. In addition, method includes epicentre antiviral lymphotropic therapy at Urin point with immunomodulating preparations of polyoxidonium and cycloferon.EFFECT: using present method provides higher clinical effectiveness in chronic diseases, burdened by herpetic infection by lymphotropic introduction of immunomodulator.1 cl, 2 tbl
ethod of activation of cognitive function in laboratory animals // 2578446
FIELD: medicine.SUBSTANCE: invention can be used to activate the cognitive functions in laboratory animals. For this purpose outbred laboratory mice are given drug "Polioksidony", which is added in an amount of 1 mg per day for 5 days, mixing it with food.EFFECT: use of this method allows you to activate the cognitive function in laboratory animals in order to select adequate controls in the study of mnemonic effects of drugs.1 cl, 3 ex

Substance having combined antiaggregant, anticoagulant and vasodilator activity, and method of producing n, n '-substituted piperazines // 2577039
FIELD: chemistry.SUBSTANCE: invention relates to N, N′-substituted piperazines of formula I and a method of producing compounds of formula II. Said compounds affect hemostasis system and exhibit antiplatelet, anticoagulant and vasodilatory properties. In general formula (I) R1 - linear or branched alkyl C1-C4, R2 - linear or branched alkyl C5-C12, G - mineral or organic C1-C4 acid or water, in general formula II R1 - linear or branched alkyl C1-C4, R2 - linear or branched alkyl C1-C12, G - mineral or organic C1-C4 acid or water. EFFECT: disclosed method enables to obtain compounds of formula II with purity of over 99 % and content of individual impurities not more than 1/10 % and sum of impurities of not more than 5/10 %.11 cl, 2 dwg, 6 tbl, 13 ex

Novel cyclopentane derivatives // 2572555
FIELD: medicine, pharmaceutics.SUBSTANCE: claimed invention relates to compounds of formula where A1 and R1, R2, R3, R4 and R5 are determined in invention formula, which are preferable inhibitors of cathepsin cycteinprotease, in particular cathepsin S or L cycteinprotease, which makes them useful as medications, especially for treatment of diabetes, atherosclerosis, aneurism of abdominal aorta, peripheral arterial disease or diabetic nephropathy.EFFECT: invention relates to methods of obtaining claimed compounds, thereof-containing pharmaceutical composition and thereof application.24 cl, 1 tbl, 255 ex

Apoptosis inducing agents for treating cancer, immune and autoimmune diseases // 2568611
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to new compounds specified in a group shown below. The compounds contain at least 5 rings including a fragment with a bridge structure with a carbon side of the central group C(O)-NH-SO2, piperidinyl, or piperazinyl, or phenyl; phenyl attached to each carbon and sulphur atom of the group C(O)-NH-SO2, wherein phenyl from the sulphur atom side is substituted by a nitro group and NH-CH2(tetrahydro-2H-pyran-4-yl or cyclohexyl) group. The compounds possess the properties of Bcl-2 antiapoptotic protein activity inhibitor and can be used in treating the diseases expressing Bcl-2 protein. These diseases are malignant diseases specified in bladder cancer, cerebral cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukaemia etc. The compounds of the present invention are specified in a group consisting of 4-(4-{acetyl[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]amino}piperidin-1-yl)-N-({4-[(cyclohexylmethyl)amino]-3-nitrophenyl}sulphonyl)benzamide; 4-(4-{benzoyl[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]amino}piperidin-1-yl)-N-({4-[(cyclohexylmethyl)amino]-3-nitrophenyl}sulphonyl)benzamide; N-({4-[(cyclohexylmethyl)amino]-3-nitrophenyl}sulphonyl)-3′-{[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]amino}biphenyl-4-carboxamide; N-({4-[(cyclohexylmethyl)amino]-3-nitrophenyl}sulphonyl)-4-(4-{(phenylacetyl)[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]amino}piperidin-1-yl)benzamide; N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulphonyl)-4-(4-{2-[(1R,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-en-2-yl]benzylidene}piperidin-1-yl)benzamide; 4-[4-(2-{5-[8-azabicyclo[3.2.1]oct-8-ylmethyl]-2-thienyl}benzyl)piperazin-1-yl]-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulphonyl)benzamide; N-({4-[(cyclohexylmethyl)amino]-3-nitrophenyl}sulphonyl)-4-(4-{(3-phenylpropanoyl)[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]amino}piperidin-1-yl)benzamide; 4-{4-[adamantan-1-ylmethyl]piperazin-1-yl}-N-({4-[(cyclohexylmethyl)amino]-3-nitrophenyl}sulphonyl)benzamide; 4-(4-{2-[adamantan-1-yl]-2-oxoethyl}piperazin-1-yl)-N-({4-[(cyclohexylmethyl)amino]-3-nitrophenyl}sulphonyl)benzamide; N-({4-[(cyclohexylmethyl)amino]-3-nitrophenyl}sulphonyl)-4-{4-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazin-1-yl}benzamide and other compounds or their therapeutically acceptable salts listed in the patent claim.EFFECT: compounds possess the properties of Bcl-2 antiapoptotic protein activity inhibitor and can be used in treating the diseases expressing Bcl-2 protein.6 cl, 1 tbl, 85 ex

ethod for correction of endothelial dysfunction with combination of rosuvastatin and thioctic acid in hypooestrogen-l-name-induced nictic oxide deficiency // 2568365
FIELD: medicine.SUBSTANCE: method involves simulating a dysfunction by performing a bilateral ovariectomy in Wistar male rats. On the 43rd postoperative days, L-nitro-arginine-methyl ester (L-NAME) is administered intragastrically in a dose of 25 mg/kg daily during 7 days. The induced dysfunction is corrected by daily intragastric administration of Rosuvastatin 0.85 mg/kg and thioctic acid 50 mg/kg during 7 days concurring with the administration of L-NAME into the rats.EFFECT: method provides activating the correction of the endothelial dysfunction in hypooestrogenemia.1 tbl, 1 ex

ethod for discovering anticonvulsant action of citicoline in pentylenetetrazole kindling model involving male c57b1/6 mice // 2567275
FIELD: medicine.SUBSTANCE: discovering process is shown in pentylenetetrazole kindling model involving male C57B1/6 mice. Action of citicoline is determined after administered in a dose of 500 mg/kg one hour before administration of pentylenetetrazole. The administration is conducted in the different regimens in different groups of animals, in particular: daily during 24 days, once on the 14th day of kindling or during 14 days of kindling.EFFECT: possibility to discover a spectrum and degree of manifestation of anticonvulsant action of the preparation.2 tbl

Therapeutic application of 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine // 2564666
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions relates to medicine and can be used for long-term treatment of depression or anxiety for longer than 12-month period in patient who previously received drug treatment, with treatment being stopped because of undesirable side effects, associated with body weight. For this purpose 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine and/or its pharmaceutically acceptable salts are applied. Also claimed are: method of long-term treatment of depression or anxiety and application of 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine and/or its pharmaceutically acceptable salts for production of medication.EFFECT: group of inventions provides reduction of side effects, associated with change of patient's body weight in long-term treatment.15 cl, 4 tbl, 2 ex

Anticancer agent involving combinations of kinase inhibitory compounds // 2560683
FIELD: medicine, pharmaceutics.SUBSTANCE: presented is a group of inventions involving an anticancer agent for combined application of a compound representing N-(2-fluor-4-{[2-({[4-(4-methylpiperazin-1-yl)piperidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide or its pharmaceutically acceptable salt of formula (I), and the compound 4-[3-chlor-4-(cyclopropylamino-carbonyl)amino-phenoxy]-7-methoxy-6-quinolinecarboxamide or its pharmaceutically acceptable salt of formula (II), (versions), an anticancer pharmaceutical composition containing the compound of formula (I) and the compound of formula (II), as well as a method of treating cancer. The compound of formula (I) , the compound of formula (II) .EFFECT: excellent anticancer effect on various types of cancer as compared to using the declared compounds separately.5 cl, 5 dwg, 5 tbl

ethod of treating and preventing neurosensory deafness and noise effects in internal ear associated with in-plant noise exposure // 2554813
FIELD: medicine.SUBSTANCE: worker is exposed to therapeutic agents and physiotherapeutic procedures as a complex. The complex involves the combined administration of Preductal MB, Nicergolin and Neiromidin in the following doses: Preductal MB 35 mg 1 tablet 2 times a day per os for 14 days; Nicergolin 4 mg intramuscularly daily 2 times a day and Neiromidin 15 mg 1 time a day for 14 days. The physiotherapeutic procedures represent 10 daily 15-min procedures of aeroionotherapy and ultratonotherapy generated by an ear electrode in the course of 5 min for each ear.EFFECT: invention enables reducing the length of treatment ensured by the functional improvement of the acoustic analyser tracts with delaying the disease progression, improving the hearing function, reducing sonitus, and increasing a whisper reception threshold.1 tbl, 2 dwg

ethylhydrofumarate prodrugs, pharmaceutical compositions containing them and methods for using // 2554347
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to a compound of formula , which is a methylhydrofumarate (MHF) prodrug. In formula (I), radicals and symbols have the values specified in the patent claim. The invention also refers to a pharmaceutical composition containing the declared methylhydrofumarate drugs, to using the declared methylhydrofumarate drugs and the pharmaceutical composition containing them, for treating diseases, such as psoriasis, asthma, multiple sclerosis, inflammatory intestinal disease and arthritis, and to a method of treating the above diseases.EFFECT: higher oral bioavailability and plasma MHF, dimethylfumarate and/or other metabolites.47 cl, 1 tbl, 54 ex

ethod for increasing motion activity at clinical stage of rehabilitation in geriatric patients with myocardial infarction, however suffered no coronary reperfusion and revascularisation // 2546410
FIELD: medicine.SUBSTANCE: establishing the diagnosis of myocardial infarction is immediately followed by prescribing trimetazidine MB, a modified-release cardiocytoprotector trimetazidine in a dose of 35 mg 2 times a day accompanied by enhancing motion activity gradually: degree Ia activity - turning to the sides; degree Ib activity - sitting for 5-10 minutes 2-3 times a day; degree IIa activity - sitting for 20 minutes, sitting meals, changing on a chair; degree IIb activity - walking along the chamber; degree IIIa activity - coming out into the corridor, unlimited sitting; degree IIIb activity - walking along the corridor, going up the stairs one level higher; degree IVa activity - going for a walk; degree IVb activity - taking 1.0-1.5km walk. The next degree is started in accordance with the patient's chronotropic response to physical exercises providing a heart rate gain to age-specific submaximal values.EFFECT: method enables providing the more effective rehabilitation of the patients by the combined use of physical exercises and drug treatment accompanied by controlling an age-specific chronotropic criterion.3 ex, 4 tbl, 1 dwg
ethod of treating inferior alveolar neuritis in filling material penetration into inferior dental canal // 2544543
FIELD: medicine.SUBSTANCE: surgical operation is preceded by administering antibacterial agents and electrical stimulation (ES) in a projection of an inferior dental foramen and a mental foramen. The electrical stimulation is ensured by Myovolna apparatus at voltage amplitude 20-30 V, current frequency 4-7 Hz, length 10 minutes in number of 10 daily procedures. That is followed by surgical removal of the filling material from the inferior dental canal. The surgical intervention is followed by administering antibacterial, immunocorrective, desensitising agents. That is combined with daily projection 10-minute exposure of an operated segment of the inferior dental canal to laser light generated by scanning laser emitter of Intradont apparatus for 12 days. The exposure is characterised by sequential scanning mode at frequency 10 Hz increased to 60 Hz for the last 2 days, at pulse laser light power 20Wt increased to 40 Wt for the last 2 days in the stochastic scanning mode.EFFECT: method provides pain syndrome and numbness reduction of the involved skin regions in the preoperative period and optimises actions aiming at postoperative blood circulation recovery in the inferior alveolar system outpatiently, as well as reducing time of rehabilitation and recovery of the patients.3 ex

Derivatives of 2-r1-4-r2-6-polynitromethyl-1,3,5-triazines, possessing antibacterial activity // 2541525
FIELD: chemistry.SUBSTANCE: invention relates to application of 2-R1-4-R2-6-polynitromethyl-1,3,5-triazines of general formula: , where n=0, X=NO2, Cl, Br, R1=R2=OR3, OAr (R3=CH3, C2H5, CH2(CH2)6CH3, CH2CH2Cl, Ar=metha-C6H4CH3), R1=OR3, OAr, R2=N(C2H5)2; n=1, X=Cl, R1=OR3, R2=NH(CH2)2NH2, N(CH2CH2)2NCH3 as compounds, which possess antibacterial activity.EFFECT: identification of compounds based on 1,3,5-triazine derivatives, which possess high antibacterial activity.3 tbl, 7 ex

Arylsulphonamide ccr3 antagonists // 2539591
FIELD: chemistry.SUBSTANCE: invention relates to compounds of formula , where: R1, R2, R3, R4, R5 and R6, each independently, denote hydrogen, halogen, cyano, nitro or C1-6alkyl; X denotes O or S; RYa denotes -C(O)R1a, -C(O)OR1a, -C(O)NR1bR1c, -C(S)NR1bR1c, -C(NNO2)NR1bR1c, -S(O)2R1a or -S(O)2NR1bR1c; under the condition that RYa is not -C(O)O-tert-butyl; and each R1a, R1b and R1c independently denotes hydrogen, C1-6alkyl, C2-6alkenyl, C3-7cycloalkyl, C6-14aryl, 5-10-member heteroaryl containing one, two or three heteroatoms selected from O, N or S, or morpholinyl; or each pair of R1b and R1c, together with the N atom to which they are bonded, independently forms morpholinyl; under the condition that the compound is not 4-(2-(3,5-dimethylphenoxy)-5-nitrophenylsulphonyl)piperazine-1-carbaldehyde; wherein each alkyl, alkenyl, aryl and 5-10-member heteroaryl, containing one, two or three heteroatoms selected from O, N or S, is optionally substituted with one or more groups, each independently selected from (a) cyano, halogen and nitro; (b) C1-6alkyl, C6-14aryl, furanyl and morpholinyl, each optionally substituted with one or more substitutes Q; (c) -C(O)Ra, -C(O)ORa, -ORa and -SRa, wherein each Q is independently selected from a group consisting of (a) cyano, halogen and nitro; (b) C1-6alkyl and C2-6alkenyl; and (c) -C(O)Re, -C(O)ORe, and -SRe; where each Re, Rf and Rg independently denotes (i) hydrogen; (ii) C1-6alkyl or C2-6alkenyl, which are suitable for modulating CCR3 activity.EFFECT: obtaining compounds which are suitable for modulating CCR3 activity.41 cl, 1 tbl, 4 ex

Naphthylacetic acids // 2539185
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions refers to organic chemistry, namely to a compound of formula I and to their pharmaceutically acceptable salt or their ester, wherein W means C(H)2, C(H)2-C(H)2 or C(H)(CH3); X is specified in a group consisting of: (1) O, (2) N(H), (4) S, (5) S(O) and (6) S(O)2; Y means carbon or nitrogen; R1 is specified in a group consisting of: (1) hydrogen, (2) halogen, (3) methyl optionally substituted by fluorine, (4) C1-7alkoxygroup optionally substituted by fluorine, (5) cyano group and (6) C1-7alkylsulphonyl; R2 means hydrogen, fluorine, chlorine or C1-7alkoxygroup; R3 means hydrogen, fluorine, chlorine, bromine or methyl; R4 is specified in a group consisting of: (1) hydrogen, (2) halogen, (3) C1-7alkyl optionally substituted by fluorine, (4) C3-7cycloalkyl, and (5) ethenyl; R5 and R6 are independently from each other specified in a group consisting of: (1) hydrogen, (2) halogen, (3) C1-7alkyl, (4) cyanogroup and (5) C3-7cycloalkyl; R7 means cyano group or S(O)2-R8, wherein R8 is specified in a group consisting of: (1) C1-7alkyl, (2) C3-7cycloalkyl, (4) C1-7alkylamino group, (5) C1-7dialkylamino group, (6) lower heterocycloalkyl optionally substituted by halogen, C1-7alkyl, or C1-7alkoxycarbonyl and (7) 2-oxa-6-azaspiro[3.3]hept-6-yl, wherein lower heterocycloalkyl means a saturated or partially unsaturated non-aromatic ring fragment containing 3 to 7 atoms bound together to form a ring structure, wherein one, two or three ring atoms are heteroatoms, whereas the rest ring atoms are carbon atoms; and pharmaceutically acceptable esters represent methyl and ethyl acid esters of formula I acceptable as prodrugs. The invention also refers to a pharmaceutical composition based on the compound of formula .EFFECT: prepared are new compounds possessing the CRTH2 receptor antagonist or partial agonist activity.23 cl, 90 ex

Using compounds binding to sigma receptor ligands for treating neuropathic pain progression caused by chemotherapy // 2537226
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to medicine, and consists in using compounds that are sigma-1 receptor antagonists.EFFECT: preparing the compounds for treating or preventing neuropathic pain caused by the chemotherapy with taxane preparations with the neuropathic pain representing allodynia or hyperalgesia.8 cl, 2 tbl, 7 dwg

Compounds of n-phenyl(pyperazinyl or homopyperazinyl)benzenesulphonamide or benzenesulphonylphenyl(pyperazine or homopyperazine), suitable for treatment of diseases responding to modulation of serotonin 5-нт6 receptor // 2535200
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to the field of organic chemistry, namely to compounds of N-phenyl(pyperazinyl or homopyperazinyl)benzenesulphonamide or benzenesulphonylphenyl(pyperazine or homopyperazine), or to their physiologically acceptable acid addition salts, described by general formulas (I) and (I'), where X is a chemical bond or a group N-R4; R1 is hydrogen or methyl; R2 is hydrogen or methyl; R3 is hydrogen, C1-C3alkyl, fluorine, C1-C2alkoxy or fluorinated C1-C2alkoxy; R4 is hydrogen, C1-C4alkyl or C3-C4cycloalkyl-CH2-; R5 is hydrogen, fluorine, chlorine, C1-C2alkyl, C1-C2alkoxy or fluorinated C1-C2alkoxy; R6 is hydrogen and n is 1 or 2. The invention also relates to a pharmaceutical composition based on the compound of formula or .EFFECT: novel compounds, modulating activity of the 5HT6 receptor are obtained.35 cl, 2 tbl, 105 ex
ethod for preserving myocardium accompanying transplantation // 2535036
FIELD: medicine.SUBSTANCE: preserving the myocardium in transplantation involves perfusion and storage of the isolated heart with using a Custodiol solution at a temperature of 2-4°C. The heart tissue culture into the donor precedes a 10-12-hour infusion of Levosimendan 10 mcg/kg of body weight, while the perfusion and storage of the isolated organ is ensured by adding Levosimendan into the Custodiol solution at 10 mcg of the preparation per 1 litre of the solution. The surgical stage of the heart transplantation after the recipient's aorta de-clamping and the blood flow recovery is followed by introducing Levosimendan 12.5 mg into the continuing bypass circuit and infusing it for 1 hour.EFFECT: invention aims at preventing the ischemic and re-perfusion myocardial injuries, providing the adequate function of the donor's heart in the recipient's body.2 ex
 
2550957.
Up!